Search research articles
Contact Us
Filters
Showing results (1061-1070 of 1,351) with videos related to
Page
of 136
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G A McArthur, M Maio, A Arance, et al.
Scientific Reports
|
May 23, 2024
Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins
Sergey A Dyshlovoy, Wael Y Mansour, Natalia A Ramm, et al.
Marine Drugs
|
May 15, 2020
Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer
Sergey A Dyshlovoy, Dmitry N Pelageev, Jessica Hauschild, et al.
The British Journal of Dermatology
|
May 21, 2014
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety
J Malvehy, A Hauschild, C Curiel-Lewandrowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Cell Reports
|
April 11, 2026
Multifold increase in spinal inhibitory cell types with emergence of limb movement
David Vijatovic, Florina Alexandra Toma, Yuri Ignatyev, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Page
of 136
Search research articles
Search
Showing results (1061-1070 of 1,351) with videos related to
Sort By:
Page
of 136
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G A McArthur, M Maio, A Arance, et al.
Scientific Reports
|
May 23, 2024
Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins
Sergey A Dyshlovoy, Wael Y Mansour, Natalia A Ramm, et al.
Marine Drugs
|
May 15, 2020
Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer
Sergey A Dyshlovoy, Dmitry N Pelageev, Jessica Hauschild, et al.
The British Journal of Dermatology
|
May 21, 2014
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety
J Malvehy, A Hauschild, C Curiel-Lewandrowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Cell Reports
|
April 11, 2026
Multifold increase in spinal inhibitory cell types with emergence of limb movement
David Vijatovic, Florina Alexandra Toma, Yuri Ignatyev, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Page
of 136